Volumes of distribution and mean residence time of drugs with linear tissue distribution and binding and nonlinear protein binding

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 24, Issue 4, 1996, Pages 389-402

  Cheng, Haiyung ^a,c   Gillespie, William R ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c Watson Pharmaceuticals Inc   (United States)

Author keywords

Mean residence time; Nonlinear protein binding; Volumes of distribution

Indexed keywords

CEFTRIAXONE;

AREA UNDER THE CURVE; ARTICLE; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; MEAN RESIDENCE TIME; PHARMACOKINETICS; PRIORITY JOURNAL; STEADY STATE; THEORETICAL STUDY;

HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; PROTEIN BINDING;

EID: 0030513778     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02353519     Document Type: Article

References (26)

1. G. H. Evans, A. S. Nies, and D. G. Shand. The disposition of propranolol III. Decreased half-life and volume of distribution of a result of plasma binding in man, monkey, dog and rat. J. Pharmacol. Exp. Ther. 180:114-122 (1973).
2. A. Yacobi and G. Levy. Comparative pharmacokinetics of coumarin anticoagulants XIV. Relationship between protein binding, distribution and elimination kinetics of warfarin in rats. J. Pharm. Sci. 64:1660-1664 (1975).
3. J. R. Gillette. Factors affecting drug metabolism. Ann. N. Y. Acad. Sci. 179:43-66 (1971).
4. G. R. Wilkinson and D. G. Shand. A physiologic approach to hepatic drug clearance. Clin. Pharmacol. Ther. 18:377-389 (1975).
5. J. G. Wagner. Simple model to explain effects of plasma protein binding and tissue binding on calculated volumes of distribution, apparent elimination rate constants and clearances. Eur. J. Clin. Pharmacol. 10:425-432 (1976).
6. S. Øie and T. N. Tozer. Effect of altered plasma protein binding on apparent volume of distribution. J. Pharm. Sci. 68:1203-1205 (1979).
7. W. J. Jusko and M. Gretch. Plasma and tissue protein binding of drugs in pharmacokinetics. Drug. Metab. Rev. 5:43-140 (1976).
8. M. L. Rocci and W. J. Jusko. Dose-dependent protein binding and disposition of prednisolone in rabbits. J. Pharm. Sci. 70:1201-1204 (1981).
9. W. J. Jusko and S. T. Chiang. Distribution volume related to body weight and protein binding. J. Pharm. Sci. 71:469-470 (1982).
10. P. J. McNamara, M. Gibaldi, and K. Stoeckel. Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations. Eur. J. Clin. Pharmacol. 25:399-405 (1983).
11. E. Kruger-Thiemer, W. Diller, and P. Bunger. Pharmacokinetic models regarding protein binding of drugs. Antimicrob. Agents Chemother. 5:183-191 (1965).
12. B. K. Martin. Kinetics of elimination of drugs possessing high affinity for the plasma protein. Nature 207:959-960 (1965).
13. J. J. Coffey, F. J. Bullock, and P. T. Schoenemann. Numerical solution of nonlinear pharmacokinetic equations: Effects of plasma protein binding on drug distribution and elimination. J. Pharm. Sci. 60:1623-1628 (1971).
14. P. J. McNamara, G. Levy, and M. Gibaldi. Effect of plasma protein and tissue binding on the time course of drug concentration in plasma. J. Pharmacokin. Biopharm. 7:191-206 (1979).
15. J. G. Wagner. Biopharmaceutics and Relevent Pharmacokinetics, 1st ed., Drug Intelligence Publications, Hamilton, IL, 1971, pp. 302-317.
16. S. Øie, T. W. Guentert, and T. N. Tozer. Effect of saturable binding on the pharmacokinetics of drugs: A simulation. J. Pharm. Pharmacol. 32:471-477 (1980).
17. W. R. Gillespie. Generalized pharmacokinetic modeling for drugs with nonlinear binding: I. Theoretical framework. J. Pharmacokin. Biopharm. 21:99-124 (1993).
18. W. R. Gillespie and P. Veng-Pedersen. Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. II. Clearance concepts applied to the evaluation of distribution kinetics. J. Pharmacokin. Biopharm. 13:441-451 (1985).
19. M. Weiss. Residence time and accumulation of drugs in the body. Int. J. Clin. Pharmacol. Ther. Toxicol. 24:121-126 (1983).
20. J. H. Oppenheimer, H. L. Schwartz, and M. I. Surks. Determination of common parameters of iodothyronine metabolism and distribution in man by noncompartmental analysis. J. Clin. Endocrinol. Metab. 41:319-324 (1975).
21. L. Z. Benet and R. L. Galeazzi. Noncompartmental determination of the steady-state volume of distribution. J. Pharm. Sci. 68:1071-1074 (1979).
22. H. Cheng and W. J. Jusko. Mean residence time concepts for pharmacokinetic systems with nonlinear drug elimination described by the Michaelis Menten equation. Pharm. Res. 5:156-164 (1988).
23. H. Cheng, W. R. Gillespie, and W. J. Jusko. Mean residence time concepts for nonlinear pharmacokinetic systems. Biopharm. Drug Dispos. 15:627-641 (1994).
24. M. L. Rocci and W. J. Jusko. LAGRAN program for area and moments in pharmacokinetic analysis. Compt. Prog. Biomed. 16:203-216 (1983).
25. P. J. McNamara, M. Gibaldi, and K. Stoeckel. Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. II. Physiological significance. Eur. J. Clin. Pharmacol. 25:407-412 (1983).
26. P. Veng-Pedersen, H. Cheng, and W. J. Jusko. Regarding dose-independent pharmacokinetic parameters in nonlinear pharmacokinetics. J. Pharm. Sci. 80:608-612 (1991).